Filgotinib inhibits METTL3-mediated m6A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2026-04-01
DOI
https://doi.org/10.1038/s41698-026-01396-z
Primary Topic
RNA modifications and cancer
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Filgotinib inhibits METTL3-mediated m6A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently

Xiaofan Pu, Kexiong Qiao, Jianghao Ren, Shengnan Jia et al.
npj Precision Oncology
RNA modifications and cancer
article

Filgotinib inhibits METTL3-mediated m6A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently

Xiaofan Pu, Kexiong Qiao, Jianghao Ren, Shengnan Jia, Liping Cao, Liangjing Zhou, Zongrong Chen, Chaolei Zhang, Chengjie Xu
article en

Abstract

No abstract available for this paper.
npj Precision Oncology
Sir Run Run Shaw Hospital (CN), Children's Hospital of Zhejiang University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province
Good health and well-being
Openalex Percentile: Top 33%
RNA modifications and cancer
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.